title: After myocardial infarction carvedilol improves insulin resistance compared to metoprolol.
abstract: BACKGROUND
  Both carvedilol and metoprolol have cardioprotective effects and decrease infarct size in myocardium. We compared effects of carvedilol and metoprolol on insulin resistance and serum lipid levels after myocardial infarction.
  
  
  METHODS
  Fifty-nine patients aged between 30 and 70 and BMI = 25-30 kg/m2, who were diagnosed with myocardial infarction with ST segment elevation, were considered to be eligible for the study. Patients were randomly allocated to two different therapy protocols. Metoprolol 100 mg bid or carvedilol 25 mg bid was added to their standardized therapy regimen. Baseline to week 4 and 12, fasting blood glucose, serum lipid profile, BMI, C-peptide, insulin and homeostasis model assessment of insulin resistance (HOMA-IR) were measured.
  
  
  RESULTS
  After 12 weeks of metoprolol therapy HOMA-IR, insulin and C-peptide levels were significantly higher (p < 0.05 for all) and total cholesterol and triglyceride levels decreased significantly (p < 0.05 for all) compared to baseline. After 12 weeks of carvedilol therapy HOMA-IR, insulin and C-peptide (p < 0.05 for all), total cholesterol and triglyceride (p = 0.001 for all) decreased significantly compared to baseline. Carvedilol provided more decrease in total cholesterol and LDL levels than metoprolol (p = 0.043 and p = 0.021, respectively).
  
  
  CONCLUSIONS
  In patients after myocardial infarction, carvedilol added to background therapy improved insulin resistance and lipid profile.
authors.affiliation: Division of Endocrinology, Metabolism & Diabetes, Department of Internal Medicine, Sisli Etfal Education and Research Hospital, Istanbul, Turkey. u_74@yahoo.de
authors.forename: Okcan
authors.initials: O
authors.lastname: Basat
authors.forename: Sema
authors.initials: S
authors.lastname: Ucak
authors.forename: Selcuk
authors.initials: S
authors.lastname: Seber
authors.forename: Erkan
authors.initials: E
authors.lastname: Oztekin
authors.forename: Yuksel
authors.initials: Y
authors.lastname: Altuntas
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D002096:C-Peptide / Q000032:analysis; D002227:Carbazoles / Q000627:therapeutic use*; D000077261:Carvedilol; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D015309:Glucose Clamp Technique; D006801:Humans; D007333:Insulin Resistance; D008297:Male; D008790:Metoprolol / Q000627:therapeutic use*; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy*; D011412:Propanolamines / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
chemical_list: D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D002096:C-Peptide; D002227:Carbazoles; D008078:Cholesterol, LDL; D011412:Propanolamines; D014280:Triglycerides; D000077261:Carvedilol; D008790:Metoprolol